EU, UK Considering Expanding Kaftrio to Children Ages 6 and Older

EU, UK Considering Expanding Kaftrio to Children Ages 6 and Older

294718

EU, UK Considering Expanding Kaftrio to Children Ages 6 and Older

Regulatory agencies in the European Union and in the U.K agreed to consider expanding the use of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to children with cystic fibrosis (CF) who have at least one F508del mutation starting at age 6. The European Medicines Agency (EMA) and the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) validated an application from Vertex Pharmaceuticals, the treatments’ maker.  The MHRA and the EU Committee for Medicinal Products for Human Use will now…

You must be logged in to read/download the full post.